Precision medicine : Its application in clinical investigation and practice innovation by Munir, Pirmohamed
Munir Pirmohamed 
David Weatherall Chair of Medicine 
Department of Molecular and Clinical Pharmacology 
Institute of Translational Medicine 
University of Liverpool 
Precision Medicine: Its Application in 
Clinical Investigation and Practice 
Innovation 
Definition of Precision Medicine 
 Precision medicine is an emerging approach for disease treatment 
and prevention that takes into account individual variability in genes, 
environment, and lifestyle for each person 
2015 
Obama’s Precision 
Medicine Initiative 
$215 million 
China 
$8.2 billion 
Terminology 
Stratified Medicine in 
the NHS, ABPI, 2014 
Marker of Success 
 
We will have succeeded when this area is simply 
called: 
 
 
A Concept of Personalised Medicine  
Environmental factors 
Drug variability 
Molecular definition 
Phenotypic definition Current standard 
Disease stratification 
Pharmacogenomics 
Personalised Medicine 
Pirmohamed, Annu. Rev. Genomics Hum. 
Genet. 2014. 15:15.1–15.22 

Systems Approaches 
Topol, 
Cell, 2014 
Regulatory Approvals 
EMA SmPCs With Mandatory 
Genomic Testing 
Nov 2014: Eliglustat 
also approved with 
CYP2D6 genotyping 
Only 3 drugs outside 
the cancer area 
Malignant Melanoma and BRAF Inhibitor: 
Baseline and 2 Weeks After 
Source: Academy of Medical Sciences Report 
Somatic Gene Variants and Therapies 
Relling & Evans, Nature 2015 
 Novel trial designs – 
acceptability for registration 
 Umbrella trial – investigation 
of single tumour type but 
stratification by different 
mutations linked to specific 
candidate drugs 
 Basket study – in multiple 
tumour types but with a focus 
on one or few biomarkers 

Microbiome and Cancer Immunotherapy 
Science, 27 Nov 2015 
Snyder et al, 
Science, Nov 
2015 
 New CF drug, ivacaftor  
 Targets G551D mutation in the 
CFTR gene (4% of CF 
population) 
 Fantastic innovation with 
increases in FEV1 ~10% 
• 200 scientists 
• 600,000 compounds screened 
• In silico screening of 2.7 million compounds 
• 3 possible candidates 
Indication expanded in 2014: 
G178R, S549N, S549R, G551S, 
G1244E, S1251N, S1255P, and 
G1349D 
 
New Cardiovascular Targets 
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) 
 Gain-of-function-mutations lead to high LDL-C and premature CVD; Loss-of-
function mutations – lower plasma levels of LDL-C and lower CVD risk 
 Increased PCSK9 attenuates LDL receptor recycling resulting in higher LDL-C 
levels 
 Human monoclonal antibodies now available – lower LDL-C. Effect on 
mortality not clear yet. 
 
ANGIOPOEITIN-LIKE 4 (ANGPTL4) 
 ANGPTL4 inhibits lipoprotein lipase (which reduced lipid levels) 
 Mutations in ANGPTL4 decrease triglyceride levels and patients have 
decreased CV risk 
 Monoclonal antibodies against protein in mice lead to reduce TG 
 
 
 Childhood motor neurone 
disease 
 Deafness, speech and 
swallowing problems, face and 
limb weakness and breathing 
problems 
  Rare, autosomal recessive 
 About 60 cases reported 
 Exome sequencing 
 
Brown-Vialetto van Laere syndrome 
High dose riboflavin (Vitamin B2) 
 
Serious Adverse Drug Reactions 
Toxic Epidermal Necrolysis 
Hepatocellular hepatitis 
CPT, 2012 
HLA-B*1502 
 Faced with this choice what would you do if a patient needs to be 
prescribed CBZ? 
A. Ignore screening policy and prescribe CBZ 
B. Screen patient for HLA-B*15:02 and prescribe alternative drug if 
positive 
C. Avoid CBZ all together and prescribe an alternative 
Evidence strong 
and consistent 
Serious ADR 
potentially 
preventable 
Government willing 
to pay for the test 
 HLA-B*15:02 screening policy introduced in Hong Kong (Sept 16, 
2008): Compared 3 years before with 3 years after (111,242 
patients) 
 CBZ prescriptions declined from 16.2%  to 2.6% (other AEDs 
increased).  
 When testing used, it worked: Incidence of SJS/TEN induced by 
carbamazepine reduced (0.24% to 0%)  
 SJS/TEN induced by phenytoin increased 
 Overall incidence of AED-induced SJS/TEN remained unchanged 
(0.09% [42/45,832] vs 0.07% [39/55,326]) 
Law of Unintended Consequences 
InTernational Consortium on Drug Hypersensitivity   (ITCH) 
EU 
Australia 
Canada 
US 
Brazil 
Croatia 
Norway 
EUDRAGENE 
Sponsored by the 
International 
Serious Adverse Event  
Consortium (iSAEC) 
 12 international centres 
 50 UK centres 
 1500 patients 
SJS/TEN Patients 
25 
DRUGS SJS/TEN 
ALLOPURINOL 10 
AMOXICILLIN 16 
AMOXICILLIN/CLAVULANIC ACID 5 
AMPICILLIN 2 
BACAMPICILLIN 1 
CARBAMAZEPINE 33 
LAMOTRIGINE 18 
OTHERS 100 
PHENYTOIN 11 
SULFASALAZINE 6 
TRIMETHOPRIM/SULFAMETHOXAZOLE 26 
Total 227 
177 Caucasians Cases 
Associations of Serious Adverse 
Drug Reactions with HLA Alleles 
 Cost varies 
 Single HLA tests 
 Only available in some 
immunology 
laboratories in the NHS 
 Turnaround time is 
variable, and can be 
about 2 weeks 
Aim 
 24 HLA alleles 
 Lower cost than 
individual alleles 
 Turnaround time <48 
hours 
 Development of a 
decision support system 
Problems in Implementing HLA Gene Tests 
Multiple HLA Biomarker Panel 
Poison is in everything, 
and no thing is without 
poison. The dosage makes 
it either a poison or a 
remedy 
 
 
Paracelsus, 1493-1541 
Dose = exposure 
 
Variation in Drug Exposure as a 
Result of Renal Impairment 
 Example: Aztreonam SmPC 
 “after an initial usual dose, the dosage of aztreonam 
should be halved in patients with estimated creatinine 
clearances between 10 and 30 mL/min/1.73 m2”  
 Many different examples in hepatic and renal impairment with 
dose instructions based on PK studies and occasionally PK-PD 
modelling 
 No need for RCTs – in fact, would be impractical 
 
Variation in Drug Exposure as a 
Result of Genetic Polymorphism 
 A genetic polymorphism leading to same degree of change in drug 
exposure as renal impairment is often ignored and/or RCT data are 
required for implementation 
 However, many patients will have genomic data in healthcare 
records (for example, from 100K genome project)  
 Some patients may present with direct to consumer genetic tests 
 Should these variants be ignored, and conventional dosing used? 
 Or should the same principles as applied to renal/hepatic 
impairment be used for genetic polymorphisms to enable more 
precise dosing? 
 
Eliglustat 
 Glucosylceramide 
synthetase inhibitor 
 Licensed for Gaucher’s 
disease by FDA in 2014 
 CYP2D6 and CYP3A4 
substrate 
 CYP2D6 EMs or IMs: 
84mg orally twice daily 
 CYP2D6 PMs: 84mg 
orally once daily 
 
 Number of users UK: 
600,000 
 Dose (mg) range per day: 
0.5-20  
 Fold variability in dose: 
40 
 Major bleeding rate per 100-
person years: 
   2.6 
 Ranking in ADR list: 
   3 
 
 
 
 
Warfarin  
Approved for human use in 1954 
 

Pharmacogenetic-Based Dosing:  Warfarin 
Randomised Controlled Trial 
  FP7 sponsored EU trials 
 454 patients 
 226 in genotype arm 
 228 in standard care arm 
 Point of Care test for 
genotyping 
European Union Pharmacogenetics 
of AntiCoagulant Therapy 
Genotyped arm 
%TTR 
Standard dosing 
(control) arm 
%TTR 
Adjusted 
Difference 
P value 
ITT ANALYSIS (n= 211 vs 216) 
67.4% 60.3% 7% P<0.001 
PER-PROTOCOL (n=166 vs 184) 
68.9% 62.3% 6.6% P=0.001 
PRIMARY OUTCOME MEASURE: Percent time within therapeutic INR range 2.0-
3.0 (TTR) during 12 weeks following the initiation of warfarin therapy 
EU-PACT Cost Effectiveness 
incremental cost-effectiveness ratios (ICERs) 
were £6,702 and 253,848 SEK per QALY  gained 
 Increase pace of progress 
which is only possible through 
involvement of many 
stakeholders 
 Linking of biomedical and 
health informatics systems 
 Incentives to develop stratified 
medicine products 
 Adoption 
 Need for collaboration 
 

 
 Deep phenotyping can be 
defined as the precise and 
comprehensive analysis of 
phenotypic abnormalities 
in which the individual 
components of the 
phenotype are observed 
and described 
Deep Phenotyping 
Delude, Nature, Nov 2015 
Are our health records up to the challenge of deep phenotyping? 
 
http://www.slideshare.net/maryam_kk/kaimrc-2014-arepathwayseffectiveakiakram 
Concluding Thoughts 
 Landscape is highly positive, but many aspects are at an early stage 
and thus aspirational.  The challenge will be to get them to work 
 Electronic health records and connectivity is very important, but key 
issues will need to be tackled 
 The focus is very much on new drugs and partnership with Pharma 
Industry, which is of course important. 
 However, most of the drugs used are off-patent, and the same issues 
of variability are seen.  We could learn a lot, more quickly, by more 
funding in this area. 
 Important not to forget about drug safety and drug dose 
 We need buy-in of healthcare systems (re-engineering of pathways 
and education and training) 
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